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Abstract 
Introduction: The human papillomavirus (HPV) causes premalignant and 
malignant lesions of the cervix. The development of vaccines has helped 
to prevent diseases related to HPV. Randomized controlled trials (RCTs) 
are the gold standard by which health care professionals and others make 
decisions about treatment effectiveness. 
Objective: Our objective was to assess the reporting quality of RCTs 
published the last 10 years, examining the efficacy of HPV vaccines in 
cervical cancer prevention using a standardized tool based on the 
Consolidated Standards of Reporting Trials (CONSORT) statement. 
Methods: Quality was assessed according to the methodological items in 
the CONSORT statement. We searched one database, namely, Pubmed. 
Detailed quality coding was conducted on RCTs, published in English 
language, between 2006 and 2015. Reporting was evaluated overall, and 
for pre- and post-CONSORT periods. 
Results: 19 of the 37 items (primary and secondary) were reported in less 
than 50% of the studies. After comparison of the two periods, a non-
significant difference (p>0.05) was detected in all items. 
Conclusion: The quality of the reports on RCTs of efficacy of hpv 
vaccines in cervical cancer prevention between 2006 and 2015 is 
moderate. Comparing two time periods, i.e. 2006-2009 and 2010-2015 
we noticed there was a non-statistical significant improvement after 
CONSORT 2010 statement. Thus, researchers should be urged to 
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Introduction 
   HPV is a group of more than 150 related viruses, more than 40 of which 
are typically transmitted through sexual contact and infect the anogenital 
region of males and females. In particular, HPV16 and HPV18 are known 
to cause around 70% of cervical cancer cases and the greatest risk of 
cervical cancer. HPV is a very common virus. Every year, over 27,000 
women and men are affected by a cancer caused by HPV. Persistent HPV 
infection can cause cervical and other cancers. HPV vaccines are 
vaccines that are used to prevent HPV infection and therefore cervical 
cancer. 
   Randomized controlled trials (RCTs) are the gold standard by which 
health care professionals and others make decisions about treatment 
effectiveness. RCTs provide information for one clinical intervention 
compared with another. In randomized controlled trials (RCTs), the 
participants are allocated to two groups of interventions and control for 
the comparison of some outcomes between them. So, with the 
randomized controlled trials (RCTs) we can test the efficacy and 
effectiveness of HPV vaccines in cervical cancer prevention, which is a 
good design plan to assess the efficacy of vaccines. 
   The assessment of new drugs and treatments is important to the 
clinician in the selection of best therapy. Recent methodological analyses 
indicate the inadequate reporting and design are associated with biased 
estimates of treatment effects. So, decisions about some treatments are 
difficult. It is significant to differentiate between assessing the quality of 
a trial and the quality of its reporting. The quality of a trial focuses on 
design quality. The quality of a report can be defined as the provision of 
information about the design, conduct, and analysis of the trial. 
   In the mid-1990s, an international group of clinical trialists, 
statisticians, epidemiologists, and biomedical journal editors developed 
the Consolidated Standards of Reporting Trials (CONSORT) statement. 
The CONSORT statement includes a checklist and a flow diagram for 
reporting RCTs. The checklist is designed to help authors in the reporting 
of randomised controlled trials (RCTs). Since then, the checklist has 
experienced some changes. Further meetings of the Group in 1999 and 
2000 led to the publication of the revised CONSORT statement 2001. 
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Following a meeting in January 2007, a further revision was developed 
and the CONSORT 2010 statement was published on March 24, 2010. 
The last CONSORT statement published in 2010, included 25 items. 
   We aimed to assess the quality of randomized controlled trials (RCTs) 
examining the efficacy of human papillomavirus vaccines in cervical 
cancer prevention according to the methodological items in the 
CONSORT statement 2010. 
 
Methods 
Studies Selection and Data Extraction 
   We have selected one database, namely, Pubmed to search all papers 
published between January 1, 2006 and 2015, with searching language 
limited to English. Selection of randomized controlled trials (RCTs) was 
made based on the appearance of the term “efficacy of hpv vaccines in 
cervical cancer prevention”. A total of 59 articles matched this search 
criteria. Of these, 5 were not published between 2006 and 2015, 1 was not 
published in English language, in 21 articles were not found free full texts 
and 9 were not relevant to topic. So, a final group of 23 RCTs was found. 
We have chosen all the RCTs concerning the efficacy of hpv vaccines in 
cervical cancer prevention. Among the selected, the intervention groups 
were treated with hpv vaccines. Figure I shows a flow chart for the 
selection of studies considered for inclusion. 
   A set of quality criteria for evaluating RCTs examining the efficacy of 
human papillomavirus (HPV) in cervical cancer prevention was compiled 
using criteria from the CONSORT Statement. The CONSORT statement 
of 2010 consists of 25 items (refined to 37 items, 25 primary and 12 
secondary). According to the CONSORT 2010 checklist we created an 
evaluation form for each of the 25 items. The result of each item was 
assessed by yes (1 point) or no (0 point) depending whether the author 
had reported it. 
Statistical Methods 
   Reporting was evaluated overall and in two publication periods, i.e. 
2006-2009 (pre-CONSORT), and 2010-2015 (post-CONSORT). 
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Additional, reporting was evaluated checking if there is any difference 
between the journals which endorse CONSORT, compared to those they 
don‟t. Data were analyzed using Microsoft Excel 2007 and SPSS 
software (version 22.0, IBM SPSS). We counted the number of reports 
which met the standards of CONSORT 2010, and calculated the 
percentage of application of each standard. Also, we used parametric 
statistics and we compared pre- and post-CONSORT periods calculating 
the odds ratio (OR) and the respective 95% confidence interval using 
Fisher‟s exact test. A P-value <0.05 was considered statistically 
significant.  
 
Table 1. Proportion of reporting of 25 data items in a total of 23 RCTs by publication period 
(pre- and post-CONSORT and combined)* 
 
Data items       Combined†      Pre-CONSORT       Post-CONSORT     Odds Ratio and 95% CI ¥        p-value**  
Title and Abstract 
1a                          0.30(7)                   0.14(1)                      0.37(6)                       3.6(0.35, 37.6)                               0.37 
1b                          0.43(10)                0.14(1)                      0.56(9)                       7.7(0.75, 79.8)                                0.09 
Introduction 
Background and objectives 
2a                          1.0(23)                   1.0(7)                         1.0(16)                                       -                                            -      
2b                          1.0(23)                   1.0(7)                         1.0(16)                                       -                                            - 
Methods 
Trial design 
3a                          0.48(11)                  0.29(2)                      0.56(9)                       3.2(0.47, 21.8)                               0.37 
3b                          0.04(1)                    0.0(0)                         0.06(1)                                      -                                          1.000 
Participants 
4a                          1.0(23)                   1.0(7)                         1.0(16)                                       -                                            -      
4b                          0.87(20)                 0.86(6)                      0.88(14)                     1.17(0.088, 15.46)                      1.000     
Interventions 
5                             0.83(19)                 0.71(5)                     0.88(14)                       2.8(0.3, 25.5)                                0.56 
Outcomes 
6a                          0.65(15)                  0.43(3)                      0.75(12)                      4(0.6, 26.1)                                   0.18 
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6b                          0.04(1)                     0.0(0)                        0.06(1)                                      -                                          1.000 
Sample size 
7a                          0.17(4)                     0.0(0)                         0.25(4)                                      -                                         0.27 
7b                          0.13(3)                     0.14                            0.13(2)                          0.86(0.65, 11.36)                    1.000 
Randomisation 
Sequence generation 
8a                          0.26(6)                   0.29(2)                      0.38(6)                           0.83(0.1, 6.1)                              1.000 
8b                          0.09(2)                   0.14(1)                      0.25(4)                           0.4(0.21, 7.5)                              0.53 
Allocation concealment mechanism 
 9                            0.26(6)                   0.29(2)                      0.25(4)                           0.83(0.1, 6.1)                             1.000             
Implementation 
10                          0.0(0)                      0.0(0)                         0.0(0)                                         -                                                - 
Blinding 
11a                        0.30(7)                   0.14(1)                      0.38(6)                           3.6(0.35, 37.6)                            0.37 
11b                        0.26(6)                   0.14(1)                      0.31(5)                           2.73(0.26, 29.1)                         0.6 
Statistical methods 
12a                         1.0(23)                   1.0(7)                        1.0(16)                                       -                                            -      
12b                         0.57(13)                 0.29(2)                     0.69(11)                         5.5(0.78, 38.7)                           0.17 
Results 
Participant flow 
13a                          0.65(15)                 0.57(4)                     0.69(11)                       1.65(0.26, 10.3)                           0.66 
13b                          0.61(14)                 0.57(4)                    0.63(10)                        1.25(0.21, 7.6)                          1.000 
Reqruitment 
14a                          0.09(2)                    0.0(0)                       0.13(2)                                      -                                         1.000 
14b                          0.0(0)                      0.0(0)                        0.0(0)                                        -                                               - 
Baseline data 
15                           0.78(18)                   0.71(5)                     0.81(13)                        1.7(0.22, 13.67)                         0.62             
Numbers analyses 
16                           0.35(8)                     0.14(1)                      0.44(7)                           4.67(0.45, 48.3)                        0.35        
Outcomes and estimation 
17a                         1.0(23)                   1.0(7)                        1.0(16)                                       -                                            -      
17b                         0.04(1)                   0.0(0)                        0.06(1)                                       -                                         1.000 
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Ancillary analyses 
18                           0.78(18)                   0.71(5)                     0.81(13)                          1.7(0.22, 13.67)                      0.62    
Harms 
19                           0.39(9)                     0.43(3)                      0.38(6)                            0.8(0.13, 4.87)                       1.000    
Discussion 
Limitations 
20                           0.7(16)                     0.71(5)                      0.69(11)                           0.9(0.16, 6.2)                        1.000    
Generalisability 
21                           0.78(18)                   0.71(5)                      0.81(13)                           1.73(0.22, 13.67)                  0.62    
Interpretation 
22                           0.65(15)                   0.57(4)                      0.69(11)                           1.65(0.20, 10.3)                     0.66   
Other information 
Registration 
23                           0.52(12)                   0.43(3)                      0.56(9)                              1.7(0.28, 10.3)                       0.67   
Protocol 
24                           0.30(7)                      0.29(2)                      0.31(5)                              1.14(0.16, 7.99)                  1.000   
Funding 
25                           0.7(16)                      0.86(6)                      0.63(10)                           0.28(0.03, 2.9)                       0.37   
*CONSORT=Consolidated Standards of Reporting Trials 
†The percentage of articles reporting the CONSORT item 
¥ Odds ratio of reporting an item at post-CONSORT period relative to pre-CONSORT. 
** p-values from Fisher’s exact test for testing the association between reporting an item and publication 
period. 
Combined: 2006-2015 (n=23) 
Pre-CONSORT: 2006-2009 (n=7) 
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 Non Free full text: n=21 
 Not relevant to topic: n=9 





Institutional Repository - Library & Information Centre - University of Thessaly
09/12/2017 13:07:26 EET - 137.108.70.7
Results 
   Our database searching on PubMed identified 547 articles on the 
efficacy of human papillomavirus vaccines in cervical cancer prevention. 
Of these 524 were excluded for various reasons. Reasons for study 
exclusion are given in Figure Ι. In total, 23 RCTs were selected for 
analysis and quality assessment. Of these articles, 7 were published in the 
pre-CONSORT period (2006-2009) and 16 in the post-CONSORT period 
(2010-2015). The articles were retrieved from 13 journals of which 10 
have not endorsed the CONSORT statement (Table 2). 
   The primary outcome of the study was the number and percentage of 
items on the CONSORT checklist that were reported between 2006 and 
2015. The total number and percentage of RCTs reporting each quality 
criterion is provided in Table 1 and based on 25 standards of CONSORT 
2010. 
   When the 23 RCTs are considered together, according to the 37 items in 
CONSORT 2010 checklist, only 4.3% (1/23) reported important changes 
to methods after trial commencement, changes to trial outcomes after the 
trial commenced and presentation of both absolute and relative effect 
sizes, 30.4% (7/23) mentioned „‟randomization‟‟ in the title, blinding to 
interventions and where the full trial protocol can be accessed, 65.2% 
(15/23) reported completely defined pre-specified primary and secondary 
outcome measures, the numbers of participants who were randomly 
assigned, received intended treatment, and were analysed for the primary 
outcome and trial interpretation, 78.3% (18/23) reported the baseline data 
with a table, ancillary analyses and Generalisability, 26.1% (6/23) 
reported the method used to generate the random allocation sequence, the 
Allocation concealment mechanism and the similarity of interventions, 
8.7% (2/23) reported the type of randomisation and dates defining the 
periods of recruitment and follow-up, 69.6% (16/23) reported trial 
limitations and the source of funding, 60.9% (14/23) reported losses and 
exclusions after randomisation, 39.1% (9/23) reported side effects, 47.8% 
(11/23) reported description of trial design, 43.5% (10/23) reported 
structured summary, 87% (20/23) reported settings and locations where 
the data were collected, 82.6% (19/23) reported the interventions for each 
group, 17.4% (4/23) reported how sample size was determined, 13% 
(3/23) reported explanation of any interim analyses and stopping 
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guidelines, 56.5% (13/23) reported methods for additional analyses, 
34.8% (8/23) reported the number of participants (denominator) included 
in each analysis and whether the analysis was by original assigned groups 
and 52.5% (12/23) reported the registration number and name of trial 
registry. 5 of the 37 items (2a, 2b, 4a, 12a and 17a) were reported in all 
included articles, while 2 items (10 and 14b) were not mentioned at all. 
Table 3 shows the items reported less often (<25%) and more often 
(>75%). 
   After comparison of the two periods, a non-significant improvement 
(p>0.05) was detected in all items. All the items are the same likely to be 
reported pre- and post- CONSORT 2010 (see respective OR at table 1). 
   After comparison of the journals, we noticed there was a statistical 
significant difference (p<0.05) between the journals which endorse 
CONSORT, compared to those they don‟t only on 3 items (3a, 14a, 22) 
(see table 3). 
 
Table 2: Distribution of papers by journal 
Journal Papers (%*) Consort endorser† 
Lancet Oncology 1(4.3%) YES 
The new England journal of 
medicine 
2(8.7%) NO 
Clinical and Vaccine 
Immunology 
2(8.7%) NO 
The BMJ 2(8.7%) NO 
Journal of the national cancer 
institute 
2(8.7%) YES 
The official journal of the 
Japanese cancer association 
1(4.3%) NO 
PLOS ONE 2(8.7%) YES 
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International journal of cancer 2(8.7%) NO 
American journal of 
epidemiology 
1(4.3%) NO 
Human Vaccines & 
Immunotherapeutics 
1(4.3%) NO 
The journal of infectious 
diseases 
3(13%) NO 
British journal of cancer 1(4.3%) NO 
Others 3(13%) NO 
 
Table 3. Items reported less often (<25%) and more often (>75%) and comparison between the 
journals which endorse CONSORT and Not. 
Items Reported less often 
(<25%) 
Reported more often 
(>75%) 
p-value 
Title and Abstract 
1a   1.000 
1b   0.127 
Introduction 
2a    - 
2b    - 
Methods 
3a   0.037<0.05 
3b    1.000 
4a    - 
4b    0.0539 
5    0.539 
6a   0.122 
6b    1.000 
7a    0.539 
7b    1.000 
8a   1.000 
8b    1.000 
9   1.000 
10    - 
11a   0.621 
11b   0.576 
12a    - 
12b   0.339 
Results 
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13a   0.621 
13b   1.000 
14a    0.040<0.05 
14b    - 
15    0.291 
16   1.000 
17a    - 
17b    1.000 
18    0.291 
19   0.611 
Discussion 
20   1.000 
21    0.545 
22   0.033<0.05 
Other information 
23   0.640 
24   0.621 
25   1.000 
 
Conclusion 
   There are some limitations to this study. This was a study based only on 
PubMed searching, in a 10-year period and only in English language. 
However, only 1 of the articles published in other language and 5 in other 
dates (not the last 10 years). So, the risk of bias is limited. 
   The quality of the reports on RCTs of efficacy of hpv vaccines in 
cervical cancer prevention between 2006 and 2015 is moderate. 9 key 
methodological items of the CONSORT statement seem poor (0-25%), 10 
low (26%-50%), 8 fair (51%-75%) and 10 good (76%-100%).  Also, we 
compared two time periods, i.e. 2006-2009 and 2010-2015. We noticed 
there was any statistical significant difference between pre- and post-
CONSORT 2010 in studies examining the efficacy of hpv vaccines in 
cervical cancer prevention. So, there was a non-statistical significant 
improvement after CONSORT 2010 statement. 
   Generally, the checklist improves the scientific quality of RCTs by 
assisting authors in the planning, preparing and conducting of RCTs. In 
conclusion, within the limitations of this study, we have shown that 
greater attention to quality aspects of design and reporting of RCTs in 
efficacy of hpv vaccines in cervical cancer prevention is needed and the 
adoption of the CONSORT statement should be a first step. Thus, 
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researchers should be urged to conform to the CONSORT statement 
when reporting on RCTs in future. 
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